Stockscreener 앱 받기
6.28
4.49%
0.27
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
Leerink Partnrs Has Optimistic Outlook of TRVI Q1 Earnings - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey
Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World
HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World
D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World
Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider
B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing Promising Trials - GuruFocus
Trevi Therapeutics Advances Haduvio in Clinical Trials - TipRanks
Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results - Investing.com
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PR Newswire
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study - MSN
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week - Yahoo Finance
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Analysts Increase Earnings Estimates for TRVI - Defense World
Stock Traders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - The AM Reporter
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World
Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - The Malaysian Reserve
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer - TipRanks
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond James - Defense World
Needham & Company LLC Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World
Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Kilgore News Herald
Trevi Therapeutics stock soars to 52-week high of $6.58 By Investing.com - Investing.com Australia
Trevi Therapeutics reports positive Phase 2a trial results - Investing.com India
Trevi Therapeutics reports positive Phase 2a trial results By Investing.com - Investing.com South Africa
Trevi Therapeutics Just Got a 212% Price Target Bump – Here’s Why - Wall Street Pit
Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: MOA, ROA, - openPR
Trevi Gets A Clap On The Back For Chronic Cough Data - Citeline News & Insights
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps - AOL
Leerink raises Trevi Therapeutics stock target to $11 - Investing.com
Leerink raises Trevi Therapeutics stock target to $11 By Investing.com - Investing.com Canada
2.00%
자본화:
|
볼륨(24시간):